

CancerPACTtm



Cancer Patients' Alliance for Clinical Trials

Listing of Cancer Clinical Trials in the Salinas Valley Spring 2009

Solid Tumors

1. Breast	2
2. Central Nervous System	3
3. Gastrointestinal	3
4. Gynecologic	4
5. Head and Neck	5
6. Lung	5
7. Melanoma	6
8. Prostate	6
9. Urologic	7

Hematologic Cancers

1. Leukemia	8
2. Lymphoma	9
3. Myeloma	10

Other	10
--------------------	----

Program Presented by:

Central Coast Center for Independent Living
Clinica de Salud del Valle de Salinas (CSVs)
Lorenzen Cancer Foundation
Salinas Valley Memorial Healthcare System

Printing sponsored by:

U.S. Department of Health and Human Services
Office of Minority Health, Region IX
San Francisco, California, 94103-6706
Phone: 415-437-8124

Call (toll free) 1-888-729-0244

www.CancerPACT.org

Solid Tumors

1. Breast Cancer

1. 40101 Phase III Factorial Randomized Study of Cyclophosphamide and Doxorubicin (CA)(4 vs 6 Cycles) Versus Paclitaxel (4 vs 6 cycles) as Adjuvant Therapy for Breast Cancer in Women with 0-3 Positive Axillary Lymph Nodes
2. **CALGB-40302 Phase III Trial of Endocrine Therapy With or Without Inhibition of EGF and HER2 Growth Factor Receptors: A Randomized, Double-Blind, Placebo-Controlled Trial for Postmenopausal Women with Estrogen-Receptor Positive Advanced Breast Cancer**
3. CALGB40503 A Phase III Randomized, Double-Blind, Placebo-Controlled Trial of Endocrine Therapy Alone or Endocrine Therapy plus Bevacizumab (NSC 704865; IND 7921) for Women with Hormone Receptor-Positive Advanced Breast Cancer
4. **E1105 Phase III Randomized Double-Blind Placebo-Controlled Trial of First-line Chemotherapy and Trastuzumab with or without Bevacizumab for Patients with HER-2/NEU Over-expressing Metastatic Breast Cancer**
5. E5103 Phase III Double-Blind Trial of Doxorubicin and Cyclophosphamide followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer
6. **IBCSG-2402 A Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Premenopausal Women with Endocrine Responsive Breast Cancer (SOFT)**
7. IBCSG-2502 A Phase III Trial Evaluating the Role of Exemestane Plus GnRH Analogue as Adjuvant Therapy for Premenopausal Women with Endocrine Responsive Breast Cancer (TEXT)
8. **N063D ALTTO: Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation Study: A Phase III Randomized, Multi-centre, Open-label, Study of Adjuvant Lapatinib, Trastuzumab, Their Sequence and Their Combination in Patients with HER2/ErbB2 Positive Primary Breast Cancer**
9. NSABP-B-39 Phase III Trial of Radiation Therapy in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer
10. **NSABP-B40 Phase III Randomized Trial of Neoadjuvant Therapy in Patients with Palpable and Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel when Administered Before AC with or without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR with Each of the Regimens**
11. S0221 Phase III Trial of Continuous Schedule AC + G Vs Q 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node Negative Breast Cancer
12. **S0226 Phase III Randomized Trial of Anastrozole Versus Anastrozole and Fulvestrant as First Line Therapy for Post Menopausal Women with Metastatic Breast Cancer**
13. S0307 Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer

Program Presented by:

Central Coast Center for Independent Living
 Clinica de Salud del Valle de Salinas (CSVS)
 Lorenzen Cancer Foundation
 Salinas Valley Memorial Healthcare System

Printing sponsored by:

U.S. Department of Health and Human Services
 Office of Minority Health, Region IX
 San Francisco, California, 94103-6706
 Phone: 415-437-8124

14. **S0500 Phase III Randomized Trial to Test the Strategy of Changing Therapy versus Maintaining Therapy for Metastatic Breast Cancer Patients who Have Elevated Circulating Tumor Cell Levels at First Follow Up Assessment**
15. E1104 Phase I/II Study of Suberoylanilide Hydroxamic Acid (SAHA) in Combination with Trastuzumab (Herceptin) in Patients with Advanced Metastatic and/or Local Chest Wall Recurrent Her-2 Amplified Breast Cancer
16. **S0230 Phase II Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer**
17. PACCT-1 Genomic profiling for breast cancer in node negative, ER-Positive and /or PR-Positive breast cancer candidate for adjuvant cytotoxic therapy in addition to hormonal therapy
18. **E2Z04 Quality of Life in Female Breast Cancer Survivors and Their Spouse, Partner, or Acquaintance**

2. Central Nervous System Tumors

1. N0574 Phase III Randomized Trial of the Role of Whole Brain Radiation Therapy in Addition to Radiosurgery in Patients with One to Three Cerebral Metastases
2. **E1F05 Phase II Study of Rituximab Given in Conjunction with Standard Chemotherapy in Primary Central Nervous System (CNS) Lymphoma**

3. Gastrointestinal Cancers

A. Colorectal Cancer

1. C80405 Phase III Trial of Irinotecan / 5-FU / Leucovorin or Oxaliplatin / 5-FU / Leucovorin with Bevacizumab, or Cetuximab (C225), or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum
2. **E5202 Phase III Randomized Study Comparing 5-FU, Leucovorin and Oxaliplatin versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers**
3. E5204 Phase III Intergroup Randomized Study of Postoperative Oxaliplatin, 5-Fluorouracil and Leucovorin vs Oxaliplatin, 5-Fluorouracil, Leucovorin and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Preoperative Chemoradiation
4. **N0147 Phase III Randomized Trial of Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) with or without Cetuximab (C225) after Curative Resection for Patients with Stage III Colon Cancer**
5. NSABPR04 Phase III Clinical Trial Comparing Preoperative Radiation Therapy and Capecitabine with or without Oxaliplatin with Preoperative Radiation Therapy and Continuous Intravenous Infusion of 5-Fluorouracil with or without Oxaliplatin in the Treatment of Patients with Operable Carcinoma of the Rectum

Program Presented by:
 Central Coast Center for Independent Living
 Clinica de Salud del Valle de Salinas (CSVS)
 Lorenzen Cancer Foundation
 Salinas Valley Memorial Healthcare System

Printing sponsored by:
 U.S. Department of Health and Human Services
 Office of Minority Health, Region IX
 San Francisco, California, 94103-6706
 Phone: 415-437-8124

Call (toll free) 1-888-729-0244
www.CancerPACT.org

6. **S0518 Phase III Prospective Randomized Comparison of Depot Octreotide plus Interferon Alpha versus Depot Octreotide plus Bevacizumab (NSC #704865) in Advanced, Poor Prognosis Carcinoid Patient**
7. S0600 Phase III Trial of Irinotecan-Based Chemotherapy Plus Cetuximab (NSC-714692) with or without Bevacizumab (NSC-704865) as Second-Line Therapy for Patients with Metastatic Colorectal Cancer who have Progressed on Bevacizumab with Either FOLFOX, OPTIMOX, or XELOX
8. **E3204 Phase II Study of Preoperative Radiation with Concurrent Capecitabine, Oxaliplatin and Bevacizumab Followed by Surgery and Postoperative 5-FU, Leucovorin, Oxaliplatin (FOLFOX) and Bevacizumab in Patients with Locally Advanced Rectal Cancer**
9. E3205 Phase II Trial of Cetuximab Plus Cisplatin, 5-Fluorouracil and Radiation in Immunocompetent Patients with Anal Carcinoma
10. **E4203 Phase II Study of Treatment Selection Based Upon Tumor Thymidylate Synthase Expression in Previously Untreated Patients with Metastatic Colorectal Cancer**
11. E4206 A Phase II Clinical and Biologic Study of AMG 706 and Octreotide in Patients with Low-Grade Neuroendocrine Tumors

B. Esophageal Cancer

1. **CALGB-80101 Phase III Intergroup Trial of Adjuvant Chemoradiation After Resection of Gastric or Gastroesophageal Adenocarcinoma**
2. RTOG-0436 A Phase III Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin and Radiation for Patients With Esophageal Cancer Who Are Treated Without Surgery
3. **E2205 A Phase II Study to Measure Response Rate and Toxicity of Neo-adjuvant Chemoradiotherapy with Oxaliplatin (OX) and Infusional 5-Fluorouracil (5-FU) Plus Cetuximab Followed by Post-Operative Docetaxel and Cetuximab in Patients with Operable Adenocarcinoma of the Esophagus**
4. 80403 Randomized Phase II Study of ECF-C, IC-C, or Folfox-C in Metastatic Esophageal and GE Junction Cancer

C. Pancreatic Cancer

1. **S0727 A Phase I and Randomized Phase II Trial of Gemcitabine + Erlotinib (NSC-718781) + IMC-A12 (NSC-742460) vs. Gemcitabine + Erlotinib as First Line Treatment in Patients with Metastatic Pancreatic Cancer**

4. Gynecologic Cancers

Program Presented by:

Central Coast Center for Independent Living
 Clinica de Salud del Valle de Salinas (CSVS)
 Lorenzen Cancer Foundation
 Salinas Valley Memorial Healthcare System

Printing sponsored by:

U.S. Department of Health and Human Services
 Office of Minority Health, Region IX
 San Francisco, California, 94103-6706
 Phone: 415-437-8124

A. Ovarian / Peritoneal Cancer

1. GOG 0198 Randomized study of Tamoxifen vs Thalidomide in Patients with Biochemical Recurrence-only Epithelial Ovarian Cancer, Cancer of the Fallopian Tube, and Primary Peritoneal Carcinoma After Chemotherapy
2. **IBCSG-2402 A Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Premenopausal Women with Endocrine Responsive Breast Cancer (SOFT)**

B. Uterine Cancer

1. GOG0209 Trial of Doxorubicin (Adriamycin)/Cisplatin (Platinol)/Paclitaxel (Taxol)/ G-CSF (Neupogen) vs Carboplatin/Paclitaxel in Patients with State III & IV or Recurrent Endometrial Cancer

5. Head & Neck Cancer

1. **E1305 A Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer**

6. Lung

1. **AVF-3991n Phase IV Study of Avastin in Combination With Chemotherapy for Treatment of Colorectal Cancer and Non-Small Cell Lung Cancer (ARIES) (Monterey Bay Oncology)**
2. 140503 Phase III Randomized Trial of Lobectomy versus Sublobar Resection for Small (≤ 2 cm) Peripheral Non-Small Cell Lung Cancer
3. **CALGB-30610 Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin and Etoposide**
4. E1505 A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (≥ 4 cm) - IIIA Non-Small Cell Lung Cancer (NSCLC)
5. **E5597 Phase III Chemoprevention Trial of Selenium Supplementation in Persons with Resected Stage I Non-Small Cell Lung Cancer**
6. N0723 A Phase III Biomarker Validation Study of Second-Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Randomized to Pemetrexed Versus Erlotinib
7. **RTOG-0617 A Randomized Phase III Comparison of Standard-Dose (60 Gy) Versus High-Dose (74 Gy) Conformal Radiotherapy with Concurrent and Consolidation Carboplatin/Paclitaxel in Patients with Stage IIIA/IIIB Non-Small Cell Lung Cancer**
8. S0526 Phase II Trial of Pemetrexed in Patients with Selected Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC)

Program Presented by:

Central Coast Center for Independent Living
 Clinica de Salud del Valle de Salinas (CSVS)
 Lorenzen Cancer Foundation
 Salinas Valley Memorial Healthcare System

Printing sponsored by:

U.S. Department of Health and Human Services
 Office of Minority Health, Region IX
 San Francisco, California, 94103-6706
 Phone: 415-437-8124

9. **E5501 Phase II Study: Sequencing Topoisomerase Inhibitors for EXtensive Stage Small Cell Lung Cancer (SCLC); Topotecan Sequenced with Etoposide/Cisplatin, and Irinotecan/Cisplatin Sequenced with Etoposide**
10. S0635 Phase II Trial of the Combination of OSI-774 (Erlotinib; NSC-718781) and Bevacizumab (Rhumab VEGF; NSC-704865) in Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma with BAC Features
11. **S0636 Phase II Trial of the Combinations of OSI-774 (Erlotinib; NSC-718781) and Bevacizumab (Rhumab VEGF; NSC-704865) in Never-Smokers with Stage IIIB and IV Primary NSCLC Adenocarcinomas**
12. S0429 Phase I Study of Weekly Docetaxel and Cetuximab Chemoradiation for Poor Risk Stage III Non-Small Cell Lung Cancer
13. **S0424 Molecular Epidemiology Case-Series Study of Non-Small Cell Lung Cancer in Smoking and Non-Smoking Women and Men**
14. S0533 Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Addition of Bevacizumab (NSC-704865) in Three Cohorts of Patients with Inoperable Locally Advanced Stage III Non-Small Cell Lung Cancer
15. **S9925 Lung Cancer Specimen Repository Protocol, Ancillary**

7. Melanoma

1. E1697 Phase III Randomized Study of Four Weeks High Dose IFN-A2B in Stage T2B NO, T3A-B NO, T4A-B NO, and T1-4, N1A, 2A (microscopic) Melanoma
2. **E1602 Phase II Trial of Multi-epitope Vaccination with Melanoma Peptides for Cytotoxic T-Cells and Helper T-Cells for Patients with Metastatic Melanoma**
3. E2602 A Phase II Study of Low Dose Peginterferon Alfa-2b in Patients with Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor

8. Prostate Cancer

1. **90202 Phase III Randomized, Double Blind, Placebo-Controlled Study of Early versus Standard Zoledronic Acid to Prevent Skeletal Related Events in Men with Prostate Cancer Metastatic to Bone**
2. C90203 A Randomized Phase III Study of Neoadjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer
3. **MDA 3410 Phase III Trial Comparing Consolidation Therapy with or without Strontium-89 Following Induction Chemotherapy in Androgen-Independent Prostate Cancer**
4. JPR11 A Phase III Study of Active Surveillance Therapy Against Radical Treatment in Patients Diagnosed with Favorable Risk Prostate Cancer (START) (Limited institution participation)
5. **R0415 Phase III Randomized Study of Hypofractionated 3D-CRT/IMRT Versus Conventionally Fractionated 3D-CRT/IMRT in Patients with Favorable-Risk Prostate Cancer**

Program Presented by:
 Central Coast Center for Independent Living
 Clinica de Salud del Valle de Salinas (CSVS)
 Lorenzen Cancer Foundation
 Salinas Valley Memorial Healthcare System

Printing sponsored by:
 U.S. Department of Health and Human Services
 Office of Minority Health, Region IX
 San Francisco, California, 94103-6706
 Phone: 415-437-8124

Call (toll free) 1-888-729-0244
www.CancerPACT.org

6. R0521 Phase III Protocol of Androgen Suppression (AS) and 3DCRT/IMRT vs AS and 3DCRT/IMRT Followed by Chemotherapy with Docetaxel and Prednisone for Localized, High-Risk Prostate Cancer
7. **RTOG0534 A Phase III Trial of Short Term Androgen Deprivation with Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPORT) in Prostate Cancer Patients with a Rising PSA after Radical Prostatectomy**
8. SWOG0421 Phase III Trial of Docetaxel and Atrasentan versus Docetaxel and Placebo for Patients with Advanced Hormone Refractory Prostate Cancer
9. **E3803 Phase II Study of a Weekly Schedule of BMS-247550 for Patients with Hormone Refractory Prostate Cancer**
10. E5805 Phase II Trial of E7389 (Halichondrin B Analog), in Patients with Metastatic Hormone Refractory Prostate Cancer
11. **E3805 CHARTED: ChemoHormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer**
12. S0437 Prostate Cancer Prevention Trial (PCPT) Companion Long Term Follow Up Study for Men Diagnosed with Favourable Risk Prostate Cancer (START)

9. Urologic Cancers (other)

A. Bladder

1. **S0337 Phase III Blinded Study of Immediate Post-TURBT Instillation of Gemcitabine Versus Saline in Patients with Newly Diagnosed or Occasional Recurring Grade I/II Superficial Bladder Cancer**
2. S0353 Phase II Study of Intravesical Gemcitabine in Patients with Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
3. **R0524 A Phase I/II Trial of a Combination of Paclitaxel and Trastuzumab with Daily Irradiation or Paclitaxel Alone with Daily Irradiation Following Transurethral Surgery for Non-Cystectomy Candidates with Muscle-Invasive Bladder Cancer**

B. Kidney Cancer

1. E2805 Phase III Sunitinib or Sorafenib in Treating Patients with Kidney Cancer That Was Removed by Surgery
2. **E2804 Phase II Study of VEGF, RAF kinase and mTOR Combination Targeted Therapy (CTT) with Bevacizumab, Sorafenib and Temsirolimus in Advanced Renal Cell Carcinoma**
3. E4805 Phase II Randomized Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients with Metastatic Renal Cell Carcinoma

Program Presented by:
 Central Coast Center for Independent Living
 Clinica de Salud del Valle de Salinas (CSVS)
 Lorenzen Cancer Foundation
 Salinas Valley Memorial Healthcare System

Printing sponsored by:
 U.S. Department of Health and Human Services
 Office of Minority Health, Region IX
 San Francisco, California, 94103-6706
 Phone: 415-437-8124

Call (toll free) 1-888-729-0244
www.CancerPACT.org

Hematologic Cancers

1. Leukemia

1. **CALGB-10501 Phase III Intergroup CLL Study of Asymptomatic Patients with Untreated Chronic Lymphocytic Leukemia Randomized To Early Intervention Versus Observation with Later Treatment in the High risk Genetic Subset with IGVh Unmutated Disease**
2. E2902 Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or Remission after Primary Induction Failure or Patients over Age 60 in First Remission
3. **E2905 Phase III Randomized Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid) Alone and in Combination with Epoetin Alfa (Procrit) in Subjects with Low- or Intermediate-1 Risk MDS and Symptomatic Anemia**
4. S0521 Phase III Randomized Trial of Maintenance Versus Observation For Patients With Previously Untreated Low and Intermediate Risk Acute Promyelomic Leukemia (APL)
5. **S0106 Phase III Study of the Addition of Gemtuzumab Ozogamicin (Mylotarg) Induction Therapy Versus Standard Induction with Daunomycin and Cytosine Arabinoside Followed by Consolidation and Subsequent Randomization to Post-Consolidation Therapy with Gemtuzumab Ozogamicin (Mylotarg) or No Additional Therapy for Patients Under Age 61 With Previously Untreated De Novo Acute Myeloid Leukemia (AML)**
6. 10403 Phase II Intergroup Clinical Trial for Adolescents and Young Adults with Untreated Acute Lymphoblastic Leukemia (ALL)
7. **10404 Phase II Randomized Study of Three Fludarabine/Antibody Combinations for Patients with Symptomatic Previously Untreated Chronic Lymphocytic Leukemia**
8. E1902 Phase II Study of Reduced Intensity Allogeneic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes
9. **E1904 Phase II Study of MOAD (Methotrexate, Vincristine, L-asparaginase, and Dexamethasone) with Subcutaneous Campath (NSC 715969) for Adults with Relapsed or Refractory Acute Lymphocytic Leukemia (ALL)**
10. E1905 Phase II Randomized Trial of Azacitidine with or without the Histone Deacetylase Inhibitor Entinostat for the Treatment of Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (dysplastic type), and Acute Myeloid Leukemia with Multilineage Dysplasia
11. **E1906 Phase II Randomized Trial of Carboplatin and Topotecan; Flavopiridol, Mitoxantrone and Cytosine Arabinoside; and Sirolimus, Mitoxantrone, Etoposide and Cytosine Arabinoside for the Treatment of Adults with Primary Refractory or Initial Relapse of Acute Myelogenous Leukemia(AML)**
12. E2903 Phase II Trial of Pentostatin, Cyclophosphamide, and Rituximab (PCR) Followed By Campath-1H For Previously Treated Relapsed or Refractory Patients With Chronic Lymphocytic Leukemia
13. **E5998 Phase II Study of Initial Treatment with Methotrexate in Large Granular Lymphocytic (LGL) Leukemia**

Program Presented by:
 Central Coast Center for Independent Living
 Clinica de Salud del Valle de Salinas (CSVS)
 Lorenzen Cancer Foundation
 Salinas Valley Memorial Healthcare System

Printing sponsored by:
 U.S. Department of Health and Human Services
 Office of Minority Health, Region IX
 San Francisco, California, 94103-6706
 Phone: 415-437-8124

Call (toll free) 1-888-729-0244
www.CancerPACT.org

14. S0325 Phase IIb Study of Molecular Responses to Imatinib at Standard or Increased Doses, or Dasatinib (BMS 354825) (NSC 732517) for Previously Untreated Patients with Chronic Myelogenous Leukemia (CML) in Chronic Phase
15. **S0333 Phase II Study of Double Induction Chemotherapy for Newly Diagnosed Non-L3 Adult Acute Lymphoblastic Leukemia with Investigation of Minimal Residual Disease and Risk of Relapse Following Maintenance Chemotherapy**
16. S0353 Phase II Study of Intravesical Gemcitabine in Patients with Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
17. **S0535 Phase II Study of ATRA, Arsenic Trioxide, and Gemtuzumab Ozogamicin in Patients with Previously Untreated High-Risk Acute Promyelocytic Leukemia**
18. S0605 Phase II Study of Lenalidomide (Revlimid) (NSC-703813) for Previously Untreated Non-M3, Deletion 5q Acute Myeloid Leukemia (AML) in Patients Age 60 or Older Who Decline Remission Induction Chemotherapy
19. **R0524 A Phase I/II Trial of a Combination of Paclitaxel and Trastuzumab with Daily Irradiation or Paclitaxel Alone with Daily Irradiation Following Transurethral Surgery for Non-Cystectomy Candidates with Muscle-Invasive Bladder Cancer**
20. E3903 Ancillary laboratory protocol for collecting diagnostic material on patients considered for ECOG treatment trials for leukemia or related hematologic disorders
21. **S9910 Leukemia Centralized Reference Laboratories and Tissue Repositories**

2. Lymphoma

1. U2963n An observational Study of Treatment, Outcomes and Prognosis in Patients with Follicular Non-Hodgkins Lymphoma (Monterey Bay Oncology)
2. **CalGB 50303 Phase III Randomized Study of R-CHOP v. Dose-adjusted EPOCH-R with Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas**
3. CTN 0401 Phase III Rituxan/BEAM vs. Bexxar/BEAM with Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Persistent or Relapsed Chemotherapy Sensitive Diffuse Large B-cell Non-Hodgkin's Lymphoma
4. **S0016 Phase III Trial of CHOP + Rituximab vs CHOP + Iodine-131-Labeled Monoclonal Anti-B1 Antibody (Tositumomab) For Treatment of Newly Diagnosed Follicular Non-Hodgkin's Lymphomas**
5. E2402 Phase II Study of Cyclosporine in the Treatment of Angioimmunoblastic T-Cell Lymphoma
6. **S0350 Phase II Trial of Cisplatin Plus Etoposide Plus Gemcitabine Plus Solumedrol (PEGS) in Peripheral T-Cell Non-Hodgkin's Lymphoma**
7. S0433 Phase II Trial of Iodine-131-Labeled Monoclonal Anti-B1 Antibody (I-131 Tositumomab) in Combination With Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Rituximab Therapy for Patients With Advanced Stage Diffuse Large B-Cell NHL
8. **S0515 Phase II Trial of Standard Dose Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) and Rituximab Plus Bevacizumab for Advanced Stage Diffuse Large B-Cell NHL**
9. S0520 Phase II Study of PDX101 (NSC-726630) in Relapsed and Refractory Aggressive B-Cell Lymphomas

Program Presented by:
 Central Coast Center for Independent Living
 Clinica de Salud del Valle de Salinas (CSVS)
 Lorenzen Cancer Foundation
 Salinas Valley Memorial Healthcare System

Printing sponsored by:
 U.S. Department of Health and Human Services
 Office of Minority Health, Region IX
 San Francisco, California, 94103-6706
 Phone: 415-437-8124

Call (toll free) 1-888-729-0244
www.CancerPACT.org

10. **E2404 Bevacizumab and CHOP (A-CHOP) in Combination for Patients with Peripheral T-Cell or Natural Killer Cell Neoplasms**
11. E3404 Response-Adapted Therapy for Aggressive non-Hodgkin's Lymphomas based on early [18F] FDG-PET Scanning

3. Myeloma

1. **10104 Phase III Randomized, Double-Blind Study of Maintenance Therapy with CC-5013 (NSC # 703813, IND # 70116) or Placebo Following Autologous Stem Cell Transplantation for Multiple Myeloma**
2. E1A05 Phase III Randomized Trial of Consolidation Therapy with Bortezomib(Velcade)-Lenalidomide (Revlimid)-Dexamethasone (VRD) versus Bortezomib (Velcade)-Dexamethasone (VD) for Patients with Multiple Myeloma who have Completed a Dexamethasone Based Induction Regimen
3. **JMY10 Phase III Study of Thalidomide and Prednisone as Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma**
4. E1A06 Phase III Intergroup Randomized Controlled Trial Comparing Melphalan, Prednisone and Thalidomide (MPT) versus Melphalan, Prednisone and Lenalidomide (Revlimid)(MPR) in Newly Diagnosed Multiple Myeloma Patients who are not Candidates for High Dose Therapy
5. **S0777 Phase III Randomized Trial of CC-5013 (Lenalidomide, NSC-703813 and Low Dose Dexamethasone (LLD) versus Bortezomib (PS-341, NSC-681239), Lenalidomide and Low Dose Dexamethasone (BLLD) for Induction, in Patients with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant**
6. S0115 Phase II Trial Evaluating Modified High Dose Melphalan (100 mg/m²) And Autologous Peripheral Blood Stem Cell Supported Transplantation (SCT) For Patients with AL AMyloidosis or High Risk (greater than or equal to Age 70 or Poor Renal Function) Patients with Multiple Myeloma(A BMT Study)
7. **S0434 Phase II Trial of BAY 43-9006 (Sorafenib) (NSC-724772) in Patients with Relapsing or Resistant Multiple Myeloma**
8. E3A05 Ancillary Laboratory Protocol for Collecting Diagnostic Material on Patients Considered for Studies of Plasma Cell Disorders
9. **S0120 Prospective Observational Biologic Study of Asymptomatic Patients With Monoclonal Gammopathy and Plasma Proliferative Disorders**
10. S0309 Myeloma Specimen Repository Protocol

Other

1. **AP23573-07-302 Phase III Study of Deforolimus in Treatment of Sarcoma – SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Deforolimus)**

Program Presented by:
 Central Coast Center for Independent Living
 Clinica de Salud del Valle de Salinas (CSVS)
 Lorenzen Cancer Foundation
 Salinas Valley Memorial Healthcare System

Printing sponsored by:
 U.S. Department of Health and Human Services
 Office of Minority Health, Region IX
 San Francisco, California, 94103-6706
 Phone: 415-437-8124